Aurobindo Pharma: US reopening, traction for COVID vaccine near-term growth opportunity

Trading Calls - Equity F&O

The most positive development for the last fiscal year has been a sharp reduction in leverage which positions Aurobindo Pharma for capex commitments in the API, vaccine and biosimilars space

Anubhav Sahu